Search

The article offers information on the ERADICATE trial, conducted by Holland and colleagues, which compared the efficacy of ceftobiprole to daptomycin in treating patients with complicated Staphylococcus aureus bacteremia (SAB). The study found that both treatments had similar rates of overall treatment success, with no significant differences in microbiologic eradication, SAB-related complications, or time to S. aureus bloodstream clearance.

The article discusses a study by Zasowski et al. published in the journal "Open Forum Infectious Diseases"on the efficacy of ceftaroline and daptomycin in treating methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infection in adults. The study found that ceftaroline is a viable alternative to daptomycin and is well-tolerated, with no differences in treatment failure between the two drugs.

The article discusses the retrospective cohort study performed at the Mayo Clinic in Minnesota from February to June 2022, the first peer-reviewed publication demonstrating the efficacy of the monoclonal antibody bebtelovimab in the prevention of severe COVID-19 infection compared with nirmatrelvir/ritonavir. It mentions that the Food and Drug Administration has issued emergency use authorizations for six new monoclonal antibodies in the fight against SARS-CoV-2.

The article discusses the meta-analysis of published literature and a disproportionality analysis using Food and Drug Administration data. It provides compelling evidence that there is a significant association between statin use and daptomycin-induced musculoskeletal adverse events and hence emphasizes that statin use should be discontinued while patients are on daptomycin.

A recent study conducted in Chiba, Japan, explored the adsorption of daptomycin by a polymethylmethacrylate (PMMA) hemofilter in vitro. The research found that daptomycin was adsorbed and removed by the PMMA hemofilter, similar to teicoplanin. The study suggests that daptomycin administration via a PMMA hemofilter should be avoided during blood purification therapy. This research was supported by Grants-in-Aid for Scientific Research (KAKENHI) and has been peer-reviewed. [Extracted from the article]

A 52-year-old woman developed DRESS syndrome and a severe maculopapular rash while being treated with multiple antibiotics for septic shock, including cefazolin, piperacillin/tazobactam, vancomycin, clindamycin, daptomycin, amoxicillin, and cefalexin. The woman required an urgent allergy assessment before undergoing a hysterectomy for endometrial hyperplasia, and skin testing revealed positive delayed readings to piperacillin/tazobactam and ampicillin. This case highlights the importance of monitoring and managing adverse drug reactions in patients receiving multiple antibiotics for serious infections. [Extracted from the article]

A recent study led by researchers from the University of Melbourne has found that the antibiotic rifaximin, commonly prescribed for liver disease patients, has led to the emergence of a nearly untreatable form of the superbug vancomycin-resistant enterococcus faecium (VRE). This resistance to daptomycin, a crucial antibiotic against VRE infections, highlights the importance of responsible antibiotic use in clinical practice. The study, published in Nature, emphasizes the need for a deeper understanding of the negative impacts of antibiotic use and the importance of surveillance to detect emerging antimicrobial resistance. [Extracted from the article]

The article discusses how Staphylococcus aureus can develop resistance to daptomycin, an antibiotic, which may lead to decreased virulence in a Drosophila infection model. The study found that the acquisition of daptomycin resistance was linked to reduced pathogenic potential, possibly due to increased susceptibility to phenoloxidase in Drosophila. The research sheds light on the interplay between antimicrobial resistance, immune response, and virulence in bacterial infections. [Extracted from the article]

A 75-year-old man with a history of paraplegia and a chronic Foley catheter developed acute eosinophilic pneumonia after receiving incorrect duration of daptomycin and ertapenem for sacral osteomyelitis. He unintentionally continued the treatment for an additional 3 weeks, resulting in low-grade fevers. Laboratory tests and imaging confirmed the diagnosis of acute eosinophilic pneumonia. The man's symptoms improved after the withdrawal of daptomycin and ertapenem, without the need for corticosteroid therapy. Follow-up after 2 weeks showed improvement in his chest CT and he remained asymptomatic. [Extracted from the article]

A study conducted at a tertiary care hospital in Central India examined the susceptibility trends of clinical methicillin-resistant Staphylococcus aureus (MRSA) isolates to commonly used anti-MRSA drugs. The study found that the minimum inhibitory concentration (MIC) of vancomycin, teicoplanin, and linezolid, which are standard antimicrobial drugs for MRSA, increased over the three-year period from 2020 to 2022. While none of the MRSA isolates were resistant to vancomycin, teicoplanin, and daptomycin, two isolates showed resistance to linezolid. The study suggests that the recovery of vancomycin-intermediate S. aureus (VISA), teicoplanin-intermediate S. aureus (TISA), and linezolid-resistant MRSA strains is concerning and may indicate potential treatment failure and the emergence of resistant strains. [Extracted from the article]

A retrospective study involving 14 patients was conducted to investigate the efficacy of dalbavancin in treating prosthetic valve endocarditis, prosthetic vascular graft infection, and cardiac implantable electronic devices infection caused by methicillin-sensitive Staphylococcus aureus. The patients, aged between 50 and 80 years, had previously received other treatments such as doxycycline, rifampicin, daptomycin, ceftriaxone, cefazolin, or teicoplanin. Despite receiving dalbavancin therapy, there was no clinical success, and unfortunately, two patients died as a result of their infections. This suggests that dalbavancin may not be effective in treating these specific infections. [Extracted from the article]

A 70-year-old woman with a history of osteoporosis and bilateral knee replacement exhibited lack of efficacy during treatment with vancomycin and daptomycin for methicillin-resistant S aureus (MRSA) bacteraemia. Despite receiving vancomycin, she continued to have fevers and cultures showed MRSA growth, indicating lack of efficacy. Her treatment was switched to daptomycin, but she still grew MRSA in all cultures, indicating lack of efficacy again. Additionally, she developed cholecystitis secondary to MRSA bacteraemia. [Extracted from the article]

In a retrospective study involving 50 patients with vascular graft and endograft infections, a case was reported of a patient who developed eosinophilic pneumonia while being treated with daptomycin. The patient's age, sex, and specific treatment details were not provided. Eosinophilic pneumonia is a rare but serious side effect of daptomycin. This case highlights the need for careful monitoring and consideration of alternative treatments in patients receiving daptomycin for vascular graft and endograft infections. [Extracted from the article]

An 86-year-old woman developed eosinophilic pneumonia while receiving antibiotic therapy with daptomycin for cellulitis in her right lower extremity. She had a history of hypertension, diabetes mellitus, and cellulitis in her left lower extremity, which had resulted in a below knee amputation. After two weeks of daptomycin therapy, she experienced worsening respiratory failure and was found to have bilateral pulmonary opacifications consistent with pneumonia. She was transferred to the ICU, where her antibiotic therapy was changed and she was treated with hydrocortisone. She eventually made a full recovery and was transferred to a general medical floor. [Extracted from the article]

A recent study conducted at the Universidad de La Sabana focused on the development and characterization of antibodies for the monitoring of glycopeptide antibiotics. The researchers aimed to create new methodologies for Therapeutic Drug Monitoring (TDM) to improve patient outcomes and reduce healthcare costs. The study successfully developed antibodies capable of recognizing specific antibiotics, such as Vancomycin, Colistin, Daptomycin, and Meropenem, with good detectability. These antibodies offer a promising tool for precise and effective therapeutic monitoring, potentially enhancing treatment efficacy and patient safety. [Extracted from the article]

A 76-year-old man developed acute eosinophilic pneumonia (AEP) and eosinophilic pleural effusion (EPE) while being treated with daptomycin for a penile implant infection. Despite receiving broad-spectrum antibiotics, his condition worsened with symptoms including leukocytosis, fevers, and hypoxemia. Diagnostic tests confirmed the presence of eosinophils in his bronchoalveolar lavage and pleural effusion, and other infectious causes were ruled out. Treatment with methylprednisolone and prednisone resulted in near complete resolution of the symptoms. [Extracted from the article]

A recent research study conducted by the Faculty of Medicine has explored the use of antibiotic-containing carrier systems for sustained drug release. The study focused on a composite of b-TCP ceramic and ADA gelatin, which showed promising results in terms of mechanical properties and biodegradability. The researchers measured the dual release of daptomycin and BMP-2 over a period of 28 days and observed a release of daptomycin above the minimum inhibitory concentration by day 9. Additionally, low concentrations of BMP-2 were released from the composite. This study provides new insights into the potential use of these carrier systems in antiinfective therapies. [Extracted from the article]

A 63-year-old man with end-stage renal disease developed acquired drug resistance to dalbavancin, daptomycin, and vancomycin after being treated for methicillin-resistant Staphylococcus aureus (MRSA). He initially received ceftriaxone and azithromycin, but was later diagnosed with MRSA and treated with vancomycin. Imaging tests revealed septic emboli and an infected pseudoaneurysm, leading to surgical resection. Despite subsequent treatment with dalbavancin and daptomycin, the patient developed infective endocarditis and the resistance was associated with specific mutations. Ceftaroline-fosamil and linezolid were used as alternative therapies, and the patient underwent multiple valve replacements. No further positive cultures were detected during one year of follow-up. [Extracted from the article]

A recent study conducted at Qilu Hospital of Shandong University in Jinan, China, explored the effect of extracorporeal membrane oxygenation (ECMO) on the pharmacokinetics of daptomycin in critically ill patients. Daptomycin is commonly used to treat Gram-positive bacterial infections in this patient population. The study found that ECMO did not significantly affect the pharmacokinetic parameters of daptomycin. However, creatinine clearance was found to significantly impact the drug's clearance. Based on their findings, the researchers recommended optimal dosage regimens for critically ill patients receiving daptomycin, taking into account efficacy, safety, and the specific pathogens involved. This study provides valuable insights for healthcare professionals treating critically ill patients with daptomycin. [Extracted from the article]

A recent study conducted by researchers at the University of Georgia has found that defects in the pgsA gene contribute to increased membrane fluidity and cell wall thickening in Staphylococcus aureus, a bacterium that is often resistant to antibiotics. The study focused on daptomycin, a last-resort antimicrobial therapy used to treat infections caused by drug-resistant strains of S. aureus. The researchers discovered that mutations in the pgsA gene led to changes in the composition of the bacterial membrane, making it more resistant to daptomycin. These findings provide valuable insights into the mechanisms of antibiotic resistance in S. aureus and could potentially inform the development of new treatment strategies. [Extracted from the article]

IN JUNE OF 2018 ELITE MIDDLE-DISTANCE RUNNER ROBBY ANDREWS WAS ON FIRE. HE WAS, UNQUESTIONABLY, at the top of his game. The then-27-year-old had just run one of his fastest [...]

A 46-year-old man developed eosinophilic pneumonia while being treated with daptomycin for methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia. The patient had a medical history of end stage renal disease and presented with shortness of breath and a syncopal episode. Diagnostic tests confirmed the diagnosis of daptomycin-induced eosinophilic pneumonia. The patient was immediately taken off daptomycin and started on other medications, including corticosteroids, which resulted in a significant improvement in symptoms. [Extracted from the article]

A recent study found that overexpression of the ugtP gene, which encodes a diglucosyldiacylglycerol synthase, leads to daptomycin resistance in Bacillus subtilis. Daptomycin is an antibiotic that works by forming a complex with certain lipids in the bacterial cell membrane, causing membrane perforation. The overexpression of ugtP resulted in an increase in the amount of diglucosyldiacylglycerol (Glc2DAG) and a decrease in other phospholipids, ultimately leading to daptomycin resistance. This research provides insight into the mechanism of bacterial resistance to daptomycin and highlights the importance of understanding these mechanisms to combat antibiotic resistance. [Extracted from the article]

A 46-year-old man developed eosinophilic pneumonia while being treated with daptomycin for methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia. The patient had a medical history of end stage renal disease and presented with shortness of breath and a syncopal episode. Diagnostic tests confirmed the diagnosis of daptomycin-induced eosinophilic pneumonia. The patient was immediately taken off daptomycin and started on other medications, including corticosteroids, which resulted in a significant improvement in symptoms. [Extracted from the article]

A male neonate developed hypereosinophilia during off-label treatment with daptomycin for Methicillin-resistant Staphylococcus epidermidis (MRSE) and Staphylococcus capitis endocarditis. He exhibited lack of efficacy during treatment with meropenem and vancomycin for MRSE infection and Staphylococcus capitis endocarditis. The boy experienced complications including fetal bradycardia, respiratory distress syndrome, and septic appearance. After discontinuing vancomycin and meropenem, he was treated with off-label daptomycin, which led to significant improvement but also caused hypereosinophilia. The neonate eventually recovered and showed normal development and growth. [Extracted from the article]

A recent study conducted at Mansoura University in Egypt has developed a new method for determining the concentration of the antibiotic daptomycin in various samples. The method uses a cationic surfactant called cetyltrimethylammonium bromide (CTAB) to enhance the fluorescent signal of daptomycin, allowing for sensitive detection. The researchers found that the method was effective in determining daptomycin concentrations in commercial vials, water, and biological fluids with high accuracy. The proposed method is considered to be environmentally friendly, simple, and reliable. [Extracted from the article]

A study conducted by researchers at Aichi Medical University in Japan compared the efficacy and safety of daptomycin (DAP) plus b-lactams versus DAP monotherapy for bloodstream infections (BSI) caused by gram-positive cocci (GPC). The researchers performed a systematic review and meta-analysis of six cohorts or case-control studies. The results showed that combination therapy of DAP and b-lactams significantly reduced mortality and clinical failure rates compared to DAP monotherapy for BSI due to GPC. However, there was no significant difference in the incidence of creatine phosphokinase (CPK) elevation between the two groups. The researchers concluded that combination therapy should be considered as an option for the empirical treatment of BSI caused by GPC. [Extracted from the article]

A preprint abstract from biorxiv.org discusses the structural changes in a daptomycin-resistant strain of Staphylococcus aureus. The study found that mutations in the genes mprF, yycG, and pgsA were associated with daptomycin resistance. The resistant strain exhibited decreased phosphatidylglycerol levels, increased branched-chain fatty acids in its membrane lipids, increased membrane fluidity, and increased cell wall thickness. The study suggests that the pgsA gene contributes to daptomycin resistance by affecting membrane fluidity, cell wall thickness, and phosphatidylglycerol levels. However, it is important to note that this preprint has not been peer-reviewed. [Extracted from the article]

A study conducted at the University Hospital Salamanca in Spain has examined the genomic insights into Staphylococcus aureus isolates that exhibit diminished susceptibility to the antibiotic daptomycin. Daptomycin is an important therapeutic resource for multidrug-resistant gram-positive bacteria, but its mechanisms of action and resistance are not completely understood. The study found mutations in several genes associated with daptomycin resistance in clinical isolates of Staphylococcus aureus, with the mprF and cls1 genes showing high polymorphism. These findings suggest that daptomycin non-susceptibility in Staphylococcus aureus is achieved through different mutation combinations. [Extracted from the article]

A recent report from the University of Wisconsin School of Medicine and Public Health discusses the use of daptomycin, an antibiotic, in pediatric patients. The study found that daptomycin was safe and effective in treating serious infections caused by gram-positive bacteria in children under 13 years old. The research involved a retrospective chart review of adverse reactions and treatment outcomes in 147 pediatric patients who received at least one dose of daptomycin. The study found that while some patients experienced side effects such as loose stools and elevated liver enzymes, overall, daptomycin was well-tolerated in this population. [Extracted from the article]

A recent study conducted at the University of Patras in Greece has found that liposomal daptomycin, a drug delivery system, exhibits enhanced activity against biofilms produced by Staphylococcus aureus and Staphylococcus epidermidis strains. The researchers prepared neutral and negatively charged daptomycin-loaded liposomes using different methods and characterized them for drug encapsulation, size distribution, and other factors. The neutral liposomes showed significantly improved inhibition of bacterial growth compared to the free drug, while the negatively charged liposomes were ineffective. The study suggests that liposomal daptomycin has potential as an antimicrobial therapeutic for preventing and treating biofilms. [Extracted from the article]

A study conducted at the University General Hospital of Patras in Greece evaluated the efficacy and safety of using the antibiotic daptomycin to treat persistent coagulase-negative staphylococcal bacteremia in neonates. The study found that daptomycin monotherapy was successful in treating most of the infants, with no adverse events reported except for one case of seizures and one death due to complications of prematurity. However, the researchers noted that larger studies and randomized controlled trials are needed to confirm the safety profile of daptomycin. This information may be useful for researchers and healthcare professionals working in neonatal intensive care units. [Extracted from the article]

A recent study conducted at the University of Iowa has provided new insights into the use of daptomycin, a cyclic lipopeptide antibiotic, in treating infections caused by certain Gram-positive bacteria. The study focused on the effects of daptomycin on Clostridioides difficile, the leading cause of healthcare-associated diarrhea. Researchers observed that sub-MIC levels of daptomycin resulted in changes to the bacterial membrane and peptidoglycan synthesis. They also identified mutations in four genes that confer daptomycin resistance, shedding light on phospholipid synthesis and cell envelope biogenesis in C. difficile. The research has been peer-reviewed and published in the Journal of Bacteriology. [Extracted from the article]

A 90-year-old woman developed acute interstitial pneumonia while being treated with daptomycin for osteomyelitis. She presented to the emergency department with progressive dyspnea and her symptoms had been worsening for a week. Chest x-ray and CT scan showed bilateral opacities and significant mediastinal lymphadenopathy. The woman's daptomycin therapy was discontinued and she was treated with prednisone. [Extracted from the article]

A 75-year-old man developed acute eosinophilic pneumonia while being treated with daptomycin for osteomyelitis and discitis. He presented at the emergency department with symptoms of fever, dyspnea, cough, and hypoxia. Laboratory investigations revealed an elevated eosinophil count, and a CT scan showed lung abnormalities consistent with eosinophilic pneumonia. The man's treatment with daptomycin was discontinued, and he was started on prednisone. After a six-month period of treatment and follow-up, his symptoms and radiological abnormalities resolved. [Extracted from the article]

A 66-year-old man developed acute eosinophilic pneumonia while being treated with daptomycin for a streptococcal infection. He had been discharged from the hospital five weeks prior after being treated for the same infection. The man experienced symptoms such as dyspnea, fever, and cough, and sought medical attention multiple times. His condition was confirmed through bronchoalveolar lavage, and he was switched to a different antibiotic and started on prednisone. His symptoms improved rapidly after the change in treatment. [Extracted from the article]

A 54-year-old man developed acute eosinophilic pneumonia while being treated with daptomycin for osteomyelitis. Within two weeks of starting the treatment, he experienced respiratory failure and was transferred to the ICU. He had symptoms such as fever, difficulty breathing, and a non-productive cough. Tests showed peripheral eosinophilia and bilateral infiltrates in his lungs. The man's condition worsened despite receiving other antibiotics, but improved after daptomycin was stopped and he started receiving methylprednisolone. The acute eosinophilic pneumonia was believed to be caused by daptomycin. [Extracted from the article]

A retrospective study described three patients, aged 75-88 years, who developed acute eosinophilic pneumonia (AEP) while being treated with daptomycin, amiodarone, or minocycline. The first patient, a 75-year-old woman, developed AEP while receiving minocycline and was successfully treated with antibiotics and steroids. The second patient, an 88-year-old man, developed AEP while receiving daptomycin and was also treated with antibiotics, leading to improvement. The third patient, an 81-year-old woman, developed AEP while receiving amiodarone and was treated with steroids, resulting in improvement. All three patients survived and were discharged. [Extracted from the article]

A recent study conducted at Houston Methodist Hospital in Texas has found that the effectiveness of the antibiotic daptomycin in treating vancomycin-resistant Enterococcus faecium infections is threatened by the emergence of daptomycin non-susceptibility. Current methods for determining daptomycin minimum inhibitory concentrations (MICs) are unreliable. The study focused on the LiaX protein, which is essential for the cell envelope response to daptomycin. The researchers developed an enzyme-linked immunosorbent assay (ELISA) to detect LiaX levels and found that elevated levels were present in both daptomycin-resistant and daptomycin-susceptible strains of E. faecium. The detection of LiaX could potentially improve the accuracy of susceptibility testing and help anticipate therapeutic failure. [Extracted from the article]

Generics continue to save the U.S. healthcare system money. The latest report from IQVIA and the Association for Accessible Medicines found that in 2018, generics drove $293 billion in savings, [...]

Introduction Impetigo, a very common bacterial skin infection, is a moving target. Over the past few decades there has been a shift in the associated bacteriology and resistance patterns, making [...]

Coronavirus Vaccines As of April 23, the World Health Organization (WHO) was assessing 83 possible vaccines for COVID-19; seven are already undergoing human clinical trials. (1) Usually, vaccine development takes [...]

A recent preprint abstract discusses the mechanisms of daptomycin resistance in Staphylococcus aureus, a bacterium that causes infections. Daptomycin is an important antibiotic used as a last resort when other treatments fail. The study found that mutations in specific genes, such as mprF, yycG, and pgsA, contribute to daptomycin resistance. The resistant strain showed changes in its cell envelope, including increased membrane fluidity and cell wall thickness. The researchers also discovered that supplementing the culture broth with certain fatty acids could partially reverse the resistance. However, it is important to note that this study has not yet undergone peer review. [Extracted from the article]

A new study conducted at the University of New Mexico Health Sciences Center compared the outcomes of different treatment approaches for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia, a serious infection associated with high mortality rates. The study found that dual therapy with ceftaroline did not reduce the risk of mortality compared to monotherapy with vancomycin or daptomycin. However, patients who received infectious diseases (ID) consultations showed a significant reduction in mortality rates. The researchers concluded that further large-scale, prospective, and randomized controlled trials are needed to determine the potential benefits of dual therapy with ceftaroline for MRSA bacteremia. [Extracted from the article]

A multicenter retrospective cohort study examined the treatment outcomes of 8 patients with prosthetic joint or vascular infections between 2016 and 2018. The study found that 6 patients experienced treatment failure with daptomycin and linezolid, and two of these patients also developed asthenia, liver injury, or kidney injury while receiving dalbavancin as suppressive antibiotic therapy. The patients had various infections caused by Enterococcus faecium, Staphylococcus epidermidis, Staphylococcus intermedius, or Streptococcus gallolyticus. Some patients received alternative antibiotics, but treatment failure persisted in some cases. One patient died after starting dalbavancin, and two patients experienced adverse events related to dalbavancin. [Extracted from the article]

A recent study conducted by researchers at Ewha Womans University in Seoul, South Korea, has discovered a potential solution to the treatment challenges posed by Staphylococcus aureus infections, including methicillin-resistant S. aureus (MRSA). The study focused on a methylazanediyl bisacetamide derivative called MB6, which selectively targets MRSA membranes without observable resistance development. The researchers found that MB6 enhances the bactericidal activity of gentamicin and daptomycin, two commonly used antibiotics, against MRSA persisters. These findings suggest that MB6 could serve as a potent antimicrobial adjuvant to enhance the efficacy of existing antibiotics against persister cells. [Extracted from the article]

A study conducted by researchers at the University of Montpellier in France has investigated the development of resistance to the antibiotic daptomycin in methicillin-resistant Staphylococcus aureus (MRSA) infections. The study found that MRSA strains in two patients with bacteremia became resistant to daptomycin within three weeks of treatment. The resistance was attributed to specific mutations in proteins involved in lipid biosynthesis. The research highlights the need for monitoring daptomycin resistance in persistent MRSA bacteremia and emphasizes the importance of understanding the mechanisms of resistance to this commonly prescribed antibiotic. [Extracted from the article]

A recent preprint abstract discusses the collateral effects of daptomycin-resistant E. faecalis, a type of bacteria that causes infections. Daptomycin is an antibiotic used to treat multi-drug-resistant infections, but little is known about how the bacteria's resistance to daptomycin affects its sensitivity to other drugs. The study found that mutations in certain genes associated with daptomycin resistance led to divergent responses to different antibiotics, particularly CRO. Additionally, mutations in another gene were associated with increased sensitivity to CRO and reduced growth rate. These findings highlight the complexity of bacterial evolution and the trade-offs between resistance and growth rates. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA 69-year-old woman developed hyperkalaemia during treatment with daptomycin as antibiotic therapy. Additionally, she developed multiple bowel movements during treatment with cefepime, vancomycin and piperacillin/tazobactam as antibiotic therapy [not all dosages, routes and outcomes stated, duration of treatment to reaction onset not stated]. [Extracted from the article]

A study conducted by researchers from the Department of Pharmacy in Philadelphia, Pennsylvania, examined the use of perioperative daptomycin as a prophylactic treatment for vancomycin-resistant Enterococcus (VRE) infection in liver transplant recipients (LTR) who were colonized with VRE. The study found that perioperative daptomycin reduced the rate of VRE infections within 14 days post-transplant, but not at 90 days. The researchers suggest that future studies should explore higher doses or longer durations of perioperative daptomycin to further reduce VRE infections beyond 14 days post-transplant. [Extracted from the article]